17) pathways. This nanobody compound transcript signature inversely overlapped with described RA endotypes, indicating a potential efficacy in a broader patient population. In summary, we showed superiority of a bispecific anti-TNF/IL-6 nanobody compound or combination treatment over monospecific treatments in both in vitro and in vivo models. We anticipate improved efficacy in upcoming clinical studies.
No takes yet. Share an insight, caveat, or question.
Biesemann et al. (2023) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: